Jeffery W. Kelly
For discovering the anti-aggregation drug, tafamidis, the first effective treatment for a human amyloid disease, specifically transthyretin amyloidosis, providing the first pharmacological evidence that protein aggregation drives neurodegeneration.
Afiliado al momento del premio
Instituto de Investigación Scripps
La Jolla, Estados Unidos